| scholarly article | Q13442814 |
| P50 | author | Ravendra Garg | Q83904749 |
| P2093 | author name string | S van Drunen Littel-van den Hurk | |
| A Potter | |||
| L Latimer | |||
| V Gerdts | |||
| P2860 | cites work | Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses | Q45406272 |
| Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection | Q45769742 | ||
| Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice | Q45868048 | ||
| Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments | Q26830726 | ||
| Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. | Q30373902 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease | Q34330690 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Noninvasive delivery technologies: respiratory delivery of vaccines | Q36349694 | ||
| Viral and host factors in human respiratory syncytial virus pathogenesis | Q36483836 | ||
| The histopathology of fatal untreated human respiratory syncytial virus infection | Q38435017 | ||
| Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. | Q39328333 | ||
| Perinatal lamb model of respiratory syncytial virus (RSV) infection | Q40266020 | ||
| Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. | Q42235080 | ||
| Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. | Q42261596 | ||
| Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. | Q43185718 | ||
| The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma | Q43495704 | ||
| Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines | Q43746561 | ||
| Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005. | Q44167197 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1338-1344 | |
| P577 | publication date | 2015-01-28 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies | |
| P478 | volume | 33 |
| Q91440678 | A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice |
| Q38672711 | A novel combination adjuvant platform for human and animal vaccines. |
| Q96607427 | Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice |
| Q64068030 | Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus |
| Q40552724 | Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity. |
| Q89514925 | Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus |
| Q40076730 | Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus |
| Q40483231 | Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal pneumonia virus of mice |
| Q40096268 | Intrauterine delivery of subunit vaccines induces a systemic and mucosal immune response in rabbits. |
| Q38773273 | Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle. |
| Q40890942 | Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs |
| Q38604787 | Novel therapies and vaccines against the human respiratory syncytial virus. |
| Q51737656 | The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages. |
| Q45324627 | Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity |
Search more.